Top Markets
Coin of the day
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Pozycja w akcjach #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Cena akcji
$0.94180721
Kapitalizacja rynkowa
$22.26M
Zmiana (1 dzień)
0.38%
Zmiana (1 rok)
-14.35%
Kraj
FR
Handel Valbiotis SA (ALVAL)

Kategoria

EPS dla Valbiotis SA (ALVAL)
EPS na dzień December 2025 TTM: $-0.57
Według najnowszych raportów finansowych i ceny akcji firmy Valbiotis SA, obecny EPS (TTM) wynosi $-0.57. Na koniec roku 2023 firma miała EPS w wysokości $-0.65, spadek w porównaniu do do EPS z roku 2022, który wynosił $-1.31.
Historia EPS dla Valbiotis SA od 2015 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
2026 (TTM) $-0.57 -12.89%
2024 $-0.66 0.52%
2023 $-0.65 -50.16%
2022 $-1.31 21.14%
2021 $-1.08 73.93%
2020 $-0.62 -52.69%
2019 $-1.31 -13.46%
2018 $-1.52 37.41%
2017 $-1.10 517.05%
2016 $-0.18 -99.73%
2015 $-65.94 0.00%
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
$4.36 -858.10%
DK
$17.01 -3,058.78%
US
$42.53 -7,497.81%
US
$9.62 -1,773.47%
BE
$23.88 -4,253.77%
NL